Share
3,079 Posts.
lightbulb Created with Sketch. 875
clock Created with Sketch. 23/08/24
20:39
Share
Originally posted by stephencca:
↑
The share will go up substantially but it wont be in a month. NYX is not the sort of company that is going to attract such a boom of investors that the price will rise to $7 in a day or a month. When there are people buying in at this price there will be too many people taking a very nice profit and suppressing the share price. I have only read the short summary report but it seems that their has been a big increase in sales and profit in both womens and the other speciality. It is hard believe that the overall position ended up with another loss. Probably one offs and the payouts to settle the court case. The good thing is that the turnover of nextstellis is increasing and hopefully it gets a little bit of an exponential growth pattern. $30 million is still not much annual turnover for a pill that millions and millions of women may use. We are expecting it to grow to $150 million, so I hope there is a magic point which causes exponential growth. If all the bad one offs have been dealt with the next quarter etc should look good. I think they mentioned the distribution mechanism proprietary to MYX is increasing the profit margin in sales. This VERY VERY IMPORTANT as it gives MYX a powerful marketing tool to attract more wholesalers to sell their products via MYX. I think the business is going ahead. CONFIDENCE IS NOT SOMETHING THE BOARD CAN CREATE OVERNIGHT. AFTER A WHILE LARGE INVESTORS WILL SUDDENLY PUT MYX ON THE BUY LIST AND it could motor past $26. I have 3 different buckets at $6-60 & $10-08 & $7-86. MYX is not going to go to the lows it once did. There is too much stability in purpose, genuinely great products, and now some substantial income. If MYX can help wholesalers distribute product at larger margins that they are getting through wholesalers, and they can also sell volume, the MYX turnover will explode. These things take some time but they will create at least 500% increases within a pretty short time AFTER IT HITS THE SWEET SPOT RE MOMENTUM.
Expand
We just need to list on the US stock exchange with a dual listing and the company will get a re rate because US Pharma companies just attract far bigger multiples and MC compared to ASX counterparts.
